{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:35Z","timestamp":1778681735839,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI123383"],"award-info":[{"award-number":["R01AI123383"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01OD026569"],"award-info":[{"award-number":["K01OD026569"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM061126"],"award-info":[{"award-number":["R01GM061126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.065","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T17:32:57Z","timestamp":1580232777000},"page":"2315-2325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Isolation and characterization of new human carrier peptides from two important vaccine immunogens"],"prefix":"10.1016","volume":"38","author":[{"given":"Paeton L.","family":"Wantuch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel K.","family":"LoPilato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrod J.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Haltiwanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fikri Y.","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.065_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2000.01109.x","article-title":"Conjugate vaccines","volume":"119","author":"Goldblatt","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0010","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1080\/21645515.2018.1470726","article-title":"Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them","volume":"14","author":"Wantuch","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.01.065_b0015","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.01.065_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061451","article-title":"Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends","volume":"23","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2020.01.065_b0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1126\/science.1319610","article-title":"Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad","volume":"256","author":"Hunt","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.01.065_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fimmu.2014.00092","article-title":"Early BCR events and antigen capture, processing, and loading on MHC class II on B cells","volume":"5","author":"Avalos","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0035","series-title":"Janeway's Immunobiology","author":"Murphy","year":"2017"},{"key":"10.1016\/j.vaccine.2020.01.065_b0040","doi-asserted-by":"crossref","first-page":"U1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.01.065_b0045","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4049\/jimmunol.1700026","article-title":"T cell-mediated humoral immune responses to type 3 capsular polysaccharide of","volume":"199","author":"Middleton","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1073\/pnas.1816401115","article-title":"Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines","volume":"116","author":"Sun","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.065_b0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/glycob\/cww062","article-title":"Carbohydrates as T-cell antigens with implications in health and disease","volume":"26","author":"Sun","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2020.01.065_b0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.065_b0065","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/15680266113136660180","article-title":"Novel strategies for development of next-generation glycoconjugate vaccines","volume":"13","author":"Avci","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.vaccine.2020.01.065_b0070","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/eji.1830191209","article-title":"Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells","volume":"19","author":"Panina-Bordignon","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0075","first-page":"1","article-title":"Invasive pneumococcal disease in relation to vaccine type serotypes","author":"Wantuch","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.01.065_b0080","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.4049\/jimmunol.135.4.2319","article-title":"Carrier-induced epitopic suppression, a major issue for future synthetic vaccines","volume":"135","author":"Schutze","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0008-8749(87)90008-6","article-title":"Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms","volume":"104","author":"Schutze","year":"1987","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.1696030","article-title":"Use of prior vaccinations for the development of new vaccines","volume":"249","author":"Etlinger","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.01.065_b0095","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0100","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1128\/IAI.73.9.5835-5841.2005","article-title":"Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein","volume":"73","author":"Baraldo","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.065_b0105","first-page":"175","article-title":"Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine","volume":"251","author":"Bixler","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1389450024605436","article-title":"The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer","volume":"3","author":"Jackson","year":"2002","journal-title":"Curr Drug Targ"},{"key":"10.1016\/j.vaccine.2020.01.065_b0115","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1002\/anie.201300390","article-title":"Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid","volume":"52","author":"Cai","year":"2013","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.vaccine.2020.01.065_b0120","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1128\/iai.63.3.961-968.1995","article-title":"Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines","volume":"63","author":"de Velasco","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.065_b0125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J"},{"key":"10.1016\/j.vaccine.2020.01.065_b0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2018.10.016","article-title":"Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9","volume":"37","author":"Rodrigues-da-Silva","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.065_b0135","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1089\/hgtb.2016.114","article-title":"Preclinical evaluation of a replication-deficient recombinant adenovirus serotype 5 vaccine expressing guanylate cyclase C and the PADRE T-helper epitope","volume":"27","author":"Snook","year":"2016","journal-title":"Hum Gene Ther Meth"},{"key":"10.1016\/j.vaccine.2020.01.065_b0140","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.vaccine.2019.02.003","article-title":"Optimization of a multivalent peptide vaccine for nicotine addiction","volume":"37","author":"Zeigler","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.065_b0145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4049\/jimmunol.142.2.394","article-title":"Delineation of several DR-restricted tetanus toxin T cell epitopes","volume":"142","author":"Demotz","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0150","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/315324","article-title":"Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins","volume":"181","author":"Diethelm-Okita","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.065_b0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/infdis\/175.2.382","article-title":"Epitope repertoire of human CD4+ T cells on tetanus toxin: identification of immunodominant sequence segments","volume":"175","author":"Diethelm-Okita","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.065_b0160","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","article-title":"Several common HLA-DR types share largely overlapping peptide binding repertoires","volume":"160","author":"Southwood","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0165","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/eji.1830230219","article-title":"The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86","volume":"23","author":"Demotz","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0170","doi-asserted-by":"crossref","first-page":"e0169086","DOI":"10.1371\/journal.pone.0169086","article-title":"Definition of human epitopes recognized in tetanus toxoid and development of an assay strategy to detect ex vivo tetanus CD4+ T cell responses","volume":"12","author":"da Silva","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.065_b0175","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1128\/IAI.71.7.4186-4189.2003","article-title":"Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM197 differs depending on the serotype of the attached polysaccharide","volume":"71","author":"Leonard","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.065_b0180","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/eji.1830251202","article-title":"Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects","volume":"25","author":"Raju","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0185","first-page":"e59545","article-title":"Quantification of proliferating human antigen-specific CD4+ T cells using carboxyfluorescein succinimidyl ester","volume":"148","author":"Di Carluccio","year":"2019","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2020.01.065_b0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2004.05.001","article-title":"Polysaccharide processing and presentation by the MHCII pathway","volume":"117","author":"Cobb","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.01.065_b0195","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1021\/pr200503g","article-title":"Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells","volume":"10","author":"Bozzacco","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.vaccine.2020.01.065_b0200","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2567.2000.00032.x","article-title":"Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized by CD8+ or CD4+ T lymphocytes","volume":"100","author":"Kerblat","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2020.01.065_b0205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1399-0039.2009.01345.x","article-title":"High-resolution, high-throughput HLA genotyping by next-generation sequencing","volume":"74","author":"Bentley","year":"2009","journal-title":"Tiss Antigens"},{"key":"10.1016\/j.vaccine.2020.01.065_b0210","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.vaccine.2020.01.065_b0215","doi-asserted-by":"crossref","first-page":"40800","DOI":"10.1074\/jbc.M110.148155","article-title":"HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM","volume":"285","author":"van Lith","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.01.065_b0220","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.humimm.2007.04.005","article-title":"High-resolution HLA alleles and haplotypes in the United States population","volume":"68","author":"Maiers","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/tan.12093","article-title":"Common and well-documented HLA alleles: 2012 update to the CWD catalogue","volume":"81","author":"Mack","year":"2013","journal-title":"Tiss Antigens"},{"key":"10.1016\/j.vaccine.2020.01.065_b0230","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.4049\/jimmunol.169.12.6928","article-title":"HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity","volume":"169","author":"Castelli","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0235","first-page":"408","article-title":"Sex and gender impact immune responses to vaccines among the elderly","volume":"30","author":"Fink","year":"2015","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.vaccine.2020.01.065_b0240","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.1073\/pnas.1805268115","article-title":"Biological sex affects vaccine efficacy and protection against influenza in mice","volume":"115","author":"Fink","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.065_b0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2020.01.065_b0250","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(00)80537-3","article-title":"Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues","volume":"8","author":"Scott","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2020.01.065_b0255","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1021\/bi991393l","article-title":"Ovalbumin (323\u2013339) peptide binds to the Major Histocompatibility Complex Class II I-A protein using two functionally distinct registers","volume":"38","author":"McFarland","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2020.01.065_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010195","article-title":"Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review","volume":"19","author":"Riaz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2020.01.065_b0265","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1752-153X-5-48","article-title":"Current status of multiple antigen-presenting peptide vaccine systems: application of organic and inorganic nanoparticles","volume":"5","author":"Fujita","year":"2011","journal-title":"Chem Cent J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:31:45Z","timestamp":1778679105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20301031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20301031"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation and characterization of new human carrier peptides from two important vaccine immunogens","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}